At Ketavita Wellness Clinic, we offer specialized IV ketamine therapy for restless legs syndrome (RLS) that hasn’t responded adequately to conventional treatments. When standard RLS medications including dopamine agonists, gabapentinoids, or other therapies haven’t provided sufficient relief from the uncomfortable sensations and urge to move your legs, our ketamine infusions offer a different approach through NMDA receptor antagonism that targets the glutamatergic mechanisms implicated in RLS pathophysiology.Located in
Wyckoff, New Jersey, our clinic provides evidence-informed care from experienced medical professionals who understand how distressing and sleep-disruptive restless legs syndrome can be. We create individualized treatment protocols designed to help you achieve meaningful reduction in RLS symptoms and improved sleep quality.
Every treatment journey begins with a comprehensive evaluation where we review your RLS history including symptom characteristics, onset and progression, circadian pattern (worsening in evening/night), impact on sleep and daytime functioning, previous treatments tried including medications and their effectiveness, current medications and whether you have secondary RLS related to iron deficiency or other conditions. This assessment helps determine whether ketamine therapy is appropriate for your treatment-resistant RLS.
Restless legs syndrome is a common neurological sensorimotor disorder affecting approximately 3-10% of adults. RLS is characterized by an uncomfortable urge to move the legs, typically accompanied by unpleasant sensations described variously as crawling, pulling, tingling, aching, throbbing, or itching deep within the leg muscles. These sensations create an irresistible need to move the legs to obtain temporary relief.
RLS follows a distinctive pattern based on four essential diagnostic criteria. First, the urge to move begins or worsens during periods of rest or inactivity—symptoms appear when you’re lying down, sitting, or remaining stationary. Second, symptoms are partially or totally relieved by movement such as walking, stretching, or rubbing the legs. Relief lasts only as long as the movement continues. Third, symptoms are worse in the evening or night than during the day, following a clear circadian pattern with peak severity typically between midnight and 4 AM. Fourth, the symptoms aren’t solely accounted for by another medical or behavioral condition.
Many people with RLS also experience periodic limb movements of sleep (PLMS)—repetitive, involuntary leg jerking or twitching that occurs throughout the night, often every 20-40 seconds. These movements further fragment sleep and contribute to daytime fatigue. You may be unaware of these movements, but a bed partner often notices them.
The impact of RLS extends far beyond physical discomfort. Because symptoms peak at night when trying to rest or sleep, RLS causes severe sleep disruption with difficulty falling asleep due to symptoms appearing when lying still, frequent awakenings from periodic leg movements or uncomfortable sensations, and reduced total sleep time and poor sleep quality. Chronic sleep deprivation leads to significant daytime consequences including severe fatigue and exhaustion, impaired concentration and memory, mood disturbances including depression and anxiety, and reduced quality of life affecting work, relationships, and daily activities. Many people with moderate to severe RLS rate their quality of life as lower than those with many other chronic conditions.
RLS is classified as primary (idiopathic) or secondary. Primary RLS has no identified external cause and often has a genetic component, with about 40-60% of cases running in families. Secondary RLS results from underlying conditions including iron deficiency (the most common reversible cause), end-stage renal disease or kidney failure, pregnancy (usually resolves after delivery), peripheral neuropathy, and certain medications. Identifying and treating secondary causes when possible can resolve RLS symptoms.
Treatment-resistant RLS occurs when symptoms persist despite adequate trials of standard first-line medications. Some patients show limited initial response to dopamine agonists or gabapentinoids. Others develop tolerance over time. Augmentation—a problematic worsening of symptoms with long-term dopamine agonist use—affects many RLS patients and requires treatment changes. For these individuals with treatment-resistant RLS, alternative therapeutic approaches become necessary.
Restless legs syndrome pathophysiology involves multiple neurotransmitter systems including dopamine, iron regulation, adenosine, and increasingly recognized, glutamate. While dopamine dysfunction has been the primary focus of RLS treatment, emerging evidence points to dysregulated glutamatergic neurotransmission as an important mechanism, particularly in the sleep and arousal disturbances associated with RLS.
Neuroimaging studies using magnetic resonance spectroscopy demonstrate elevated glutamate levels in the thalamus of RLS patients compared to healthy controls. The thalamus plays critical roles in both sensory processing and sleep-wake regulation, suggesting that excess glutamate activity may contribute to both the uncomfortable sensory symptoms and the arousal disturbances characteristic of RLS.
Brain iron deficiency in RLS appears to increase glutamatergic tone. Iron serves as a cofactor for enzymes involved in dopamine synthesis and also affects adenosine receptor function. Low brain iron leads to downregulation of adenosine A1 receptors, which normally inhibit glutamate release. The resulting hyperglutamatergic state may perpetuate RLS symptoms. This mechanism helps explain why treatments targeting glutamate neurotransmission show efficacy in RLS.
Ketamine functions as a noncompetitive antagonist of NMDA receptors, blocking excessive glutamatergic signaling. By antagonizing NMDA receptors, ketamine may reduce the heightened glutamate activity implicated in RLS pathophysiology. This mechanism differs fundamentally from dopamine agonists, offering a distinct therapeutic approach for patients whose RLS doesn’t respond adequately to dopaminergic treatment.
Additional mechanisms may contribute to ketamine’s effects. Low-dose ketamine may reduce neuroinflammation at the spinal cord level. Inflammatory mediators produced through NMDA receptor activation could contribute to RLS symptoms. By blocking these receptors and associated inflammatory cascades, ketamine might reduce both sensory symptoms and motor restlessness. The anti-inflammatory properties of NMDA antagonists may play important roles in symptom relief.
Clinical observations suggest that medications affecting glutamate systems are particularly effective for improving sleep in RLS patients. Gabapentin and pregabalin inhibit presynaptic glutamate release through alpha-2-delta calcium channel modulation and are highly effective for RLS-related sleep disturbances. Methadone, which possesses NMDA receptor antagonist properties in addition to opioid activity, proves effective for treatment-resistant RLS at low doses. Ketamine’s NMDA antagonism may similarly address the sleep and arousal components of RLS.
The evidence for ketamine treating RLS comes primarily from case reports rather than controlled trials. A seminal 2002 case series reported two patients with severe, treatment-resistant RLS who experienced dramatic improvement with low-dose oral ketamine. Both patients had failed multiple conventional treatments. Within 15-20 minutes of oral ketamine administration, they reported substantial reduction in RLS symptoms from visual analog scale scores of 6-7/10 to 2/10. They continued ketamine therapy for 1-6 months with sustained benefit in both RLS symptoms and sleep quality.
Your treatment journey at Ketavita begins with a thorough evaluation to determine whether ketamine therapy is appropriate for your treatment-resistant RLS. We’ll discuss your RLS history in detail including when symptoms began and how they’ve progressed, specific characteristics of your sensations (crawling, pulling, aching, tingling, etc.), circadian pattern and timing of worst symptoms, severity on a standardized RLS rating scale, impact on sleep including difficulty falling asleep, nighttime awakenings, and total sleep time, and daytime consequences including fatigue, mood, and functioning.
Understanding your treatment history is essential: all RLS medications tried including dopamine agonists (pramipexole, ropinirole, rotigotine), gabapentinoids (gabapentin, pregabalin), opioids, benzodiazepines, others, doses and durations of each trial, effectiveness and any side effects experienced, whether you experienced augmentation with dopamine agonists, and current medication regimen. This comprehensive assessment helps determine if you meet criteria for treatment-resistant RLS and whether ketamine therapy might be appropriate.
We’ll also evaluate for secondary causes that might be contributing: recent iron studies (ferritin, iron, transferrin saturation) since iron deficiency is highly treatable, kidney function and any history of renal disease, current or recent pregnancy, medications that might worsen RLS, and other neurological conditions. Addressing any modifiable factors optimizes outcomes.
For IV ketamine therapy for RLS, treatment protocols are informed by published case reports showing benefit with low-dose ketamine. Dosing strategies differ from chronic pain protocols, emphasizing lower doses that achieve NMDA receptor antagonism without producing significant dissociative effects. Treatment typically involves a series of infusions over several weeks to establish response.
During each session, you’ll receive your ketamine infusion while resting in a private, comfortable treatment room. We monitor your vital signs continuously throughout the infusion. At the low doses used for RLS, dissociative effects are typically minimal but may include mild feelings of detachment, slight altered perception, drowsiness, and temporary relaxation.
Common side effects are generally mild and short-lasting including temporary mild dissociation during infusion, dizziness or lightheadedness, possible mild nausea, drowsiness, and temporary blood pressure elevation. These effects typically resolve within 1-2 hours after infusion completion.
After each treatment session, you’ll spend additional time in our office for recovery and monitoring before leaving. You cannot drive for 24 hours after ketamine treatment and must bring someone to drive you home.
Response to ketamine therapy for RLS varies among individuals and evidence is limited to case reports. In published cases, patients experienced substantial symptom relief within 15-20 minutes of ketamine administration, with benefits sustained over months of continued treatment. However, these represent just two documented cases. Individual response in broader populations remains uncertain.
We track your individual response using standardized RLS severity scales and sleep quality measures to assess treatment effectiveness. For patients who do respond to ketamine therapy, the protocol may involve ongoing maintenance treatments to sustain benefits, with frequency determined by individual symptom patterns.
Ketamine therapy for RLS may be appropriate if you have treatment-resistant restless legs syndrome. You may be a candidate if you have moderate to severe RLS meeting diagnostic criteria, have tried and failed adequate trials of at least two different medication classes (dopamine agonists, gabapentinoids, others), continue experiencing severe symptoms that disrupt sleep and impair functioning despite treatment, have no secondary causes that can be addressed (or secondary causes have been treated without symptom resolution), and remain significantly disabled by RLS symptoms.
Good candidates are adults with confirmed RLS diagnosis whose symptoms remain severe despite appropriate trials of conventional treatments. The limited published evidence for ketamine in RLS comes from patients with particularly refractory symptoms who had exhausted standard therapeutic options.
Certain factors may affect treatment suitability. During evaluation, we review cardiovascular health since ketamine temporarily raises blood pressure, history of psychiatric conditions, substance use history, current medications including RLS treatments and their effectiveness, iron status and whether iron supplementation has been attempted, and complete medical history including kidney function. Your comprehensive evaluation ensures safe, appropriate treatment.
It’s important to understand that ketamine therapy for RLS represents off-label use with very limited published evidence. The entire evidence base consists of two case reports from 2002 describing dramatic benefit in treatment-resistant cases, plus mentions in narrative reviews of lesser-known RLS treatments. No controlled trials have examined ketamine for RLS. The mechanism (NMDA antagonism targeting glutamate dysregulation) has theoretical support, but clinical efficacy data is minimal. We discuss this evidence limitation transparently during consultation so you can make fully informed treatment decisions.
Our ketamine protocols for treatment-resistant RLS are informed by available case reports and understanding of glutamatergic mechanisms in RLS pathophysiology. The foundational evidence comes from Kapur and Friedman’s 2002 case series showing that two patients with severe, treatment-resistant RLS experienced rapid and sustained improvement with low-dose oral ketamine. This remains the most direct clinical evidence for ketamine treating RLS.
Additional support comes from understanding that glutamate dysregulation contributes to RLS. Magnetic resonance spectroscopy studies demonstrate elevated thalamic glutamate in RLS patients. Other NMDA antagonists show RLS benefit—methadone at low doses is highly effective for treatment-resistant cases, partly through NMDA antagonism beyond opioid effects. Alpha-2-delta ligands like gabapentin and pregabalin inhibit glutamate release and effectively treat RLS. These observations support the therapeutic potential of NMDA receptor antagonism.
A 2023 narrative review examining lesser-known RLS medications identified ketamine as one potential alternative for treatment-resistant cases, noting both the limited case report evidence and the mechanistic rationale through glutamate modulation. The review emphasizes that such treatments should be considered only when standard first-line therapies prove inadequate.
Safety is paramount in all our treatments. Ketamine has been used safely in medical settings for decades, and we follow established safety protocols for subanesthetic dosing. All treatments are administered by licensed medical professionals with appropriate training, monitoring equipment, and emergency protocols.
We recognize that optimal RLS management requires comprehensive, multifaceted treatment. While ketamine may provide benefit for some patients with treatment-resistant symptoms, we strongly encourage continued engagement with comprehensive RLS care including iron supplementation if deficient (ferritin should be above 75 ng/mL for RLS), behavioral strategies including sleep hygiene and avoiding symptom triggers, treatment of comorbid conditions like depression or anxiety, regular follow-up with neurologists or sleep medicine specialists, and consideration of other evidence-based treatments for refractory RLS.
Patient education is essential to our approach. We ensure you understand how ketamine’s NMDA antagonism targets glutamate mechanisms distinct from dopamine-focused treatments, what the very limited published evidence shows (two case reports), realistic expectations given the uncertain broader efficacy beyond published cases, potential side effects and risks, alternative options for treatment-resistant RLS, and how ketamine fits into comprehensive RLS management. Informed patients with realistic expectations are better positioned to make appropriate treatment decisions.
Ketamine therapy for restless legs syndrome is typically not covered by insurance as it represents off-label use with minimal published evidence. We provide transparent pricing information during your consultation so you can make informed decisions about treatment.
IV ketamine therapy for RLS is $1,000 per session. This pricing reflects the extended infusion protocols and specialized monitoring required for chronic neurological conditions. Treatment protocols typically involve multiple infusions over several weeks for the initial treatment phase, with the specific number based on individual response and clinical judgment.
The total investment depends on your treatment protocol, whether you respond favorably to therapy, and whether ongoing maintenance treatments are needed to sustain benefits. Given the very limited outcome data beyond two published cases, we discuss realistic expectations during your consultation.
While insurance typically doesn’t cover ketamine therapy for RLS, we can provide receipts and clinical documentation that you may submit to your insurance company for possible out-of-network reimbursement. For an additional $50 fee, we can prepare detailed documentation for insurance submission. Coverage decisions are made by individual insurance companies based on their policies, and approval is not guaranteed.
If you’ve been struggling with restless legs syndrome despite trying multiple conventional treatments, IV ketamine therapy at Ketavita Wellness Clinic may be worth considering. Our approach provides a treatment option through NMDA receptor antagonism that works differently than standard RLS medications for patients with refractory symptoms.
Schedule a consultation to discuss your RLS history and treatment trials, review whether you meet criteria for treatment-resistant RLS, explore whether ketamine therapy might be appropriate given the limited but promising evidence, and develop a personalized treatment plan if you proceed with treatment.
Living with treatment-resistant restless legs syndrome severely impacts sleep and quality of life, but emerging treatment options continue to develop. Contact us today to learn whether ketamine therapy might be appropriate for your refractory RLS.
The published evidence is very limited—essentially two case reports from 2002 showing dramatic benefit in severely treatment-resistant patients. Both patients failed multiple conventional treatments but experienced substantial symptom relief with low-dose ketamine sustained over months. No controlled trials have examined ketamine for RLS. The theoretical rationale through glutamate modulation is sound, but clinical efficacy beyond these cases remains uncertain.
RLS involves multiple neurotransmitter systems including both dopamine and glutamate. Research shows elevated glutamate in the thalamus of RLS patients. Other medications targeting glutamate (gabapentin, pregabalin, methadone) effectively treat RLS, particularly the sleep and arousal components. Ketamine’s NMDA antagonism may address glutamatergic dysfunction that contributes to RLS symptoms, especially in patients who don’t respond well to dopaminergic treatment.
The limited evidence suggests ketamine may be particularly effective for sleep-related aspects of RLS. Glutamate antagonists generally improve sleep quality and arousal disturbances in RLS. Published cases noted improvement in both sensory symptoms (uncomfortable leg sensations) and sleep quality. However, with only two reported cases, we cannot definitively characterize which symptoms respond best.
Augmentation—worsening of RLS symptoms with long-term dopamine agonist use—is a common and serious problem requiring medication changes. Because ketamine works through a different mechanism (NMDA antagonism rather than dopamine), it might help patients experiencing augmentation. However, this remains theoretical as no published studies specifically examine ketamine for augmentation cases.
In the published cases, patients reported substantial symptom relief within 15-20 minutes of oral ketamine administration. However, these were individual responses that may not generalize. IV ketamine might show different time courses. We track your response carefully across multiple treatments to assess effectiveness.
Yes, typically. Most patients continue their current RLS medications during ketamine treatment. We review all your medications during consultation to ensure there are no contraindications. Never discontinue RLS medications without consulting your prescribing physician, as abrupt discontinuation can worsen symptoms.
Side effects at low doses are generally mild including temporary dissociation during infusion, dizziness, possible nausea, and drowsiness. Ketamine temporarily raises blood pressure. Serious adverse events are rare at subanesthetic doses with appropriate medical monitoring. Long-term effects of repeated ketamine for RLS are unknown given minimal published data.
Yes. For refractory RLS, evidence-based options include low-dose opioids (methadone is particularly effective), switching between medication classes, iron supplementation even if not severely deficient, combination therapy with multiple medications, and non-pharmacological approaches including pneumatic compression devices. We discuss all appropriate options during consultation.
Typically no, as ketamine for RLS represents off-label use with minimal published evidence. We can provide documentation for possible out-of-network reimbursement, but approval is unlikely and not guaranteed.
Neurological & Sleep Disorders
Conditions Treated
365 Franklin Avenue, Wyckoff, NJ 07481